AI Prescription Refills Spark Debate as Iowa Lawmakers Consider Licensing Medical Bots

WASHINGTON — A new program in Utah that lets patients skip the doctor and get prescription refills from an AI chatbot has ignited a national debate over whether machines are ready to handle tasks once reserved for physicians. And Iowa lawmakers are already watching closely.

The program, run by a company called Doctronic, allows Utah residents to refill prescriptions online through an AI chatbot without seeing a doctor. It's a convenience that supporters say could transform healthcare. But critics warn it puts patients at risk and undermines decades of medical licensing standards.

For Iowa, the issue hits close to home. State lawmakers in Des Moines have introduced legislation to formally license AI medical services, following a template from the Cicero Institute, a pro-AI think tank. The move comes as other states like Texas and Wyoming also waive rules for AI in healthcare.

How the Utah AI Refill Program Works

Doctronic launched its refill program earlier this year under a Utah “regulatory sandbox” that allows state officials to waive laws for AI companies. Patients visit a website, confirm their identity, and answer questions from the chatbot about their prescriptions and medical history. The AI then checks a national pharmacy database to verify the prescription. If everything is in order, the AI renews the prescription and sends it to a local pharmacy. If there are issues, the chatbot transfers the patient to a human doctor.

The company's list of 190 refillable medications includes blood thinners, which can become dangerous if a patient develops conditions like stomach ulcers. Dr. Alan Smith, a family physician who chairs Utah's medical licensing board, says the risks are real.

“Many times when I see people after six months, I find that their medical history or situation has changed,” Smith said. “Just because something was prescribed before does not mean it's appropriate now.”

Iowa Lawmakers Eye Licensing for AI Medical Services

Iowa is among several states considering legislation to formally license AI medical services. The bills are based on a template from the Cicero Institute, a conservative think tank co-founded by Palantir co-founder Joe Lonsdale. The institute argues that current laws are outdated and that AI can help expand access to care.

“Whoever goes first is going to take the slings and arrows because there's economic interests, concerns about the workforce and what that's going to mean for jobs,” said Adam Meier, Cicero's director for health policy.

But critics say the pushback is not just about jobs. The American Medical Association has warned that “prescription renewals aren't routine checkboxes.” Dr. Eric Bressman of the University of Pennsylvania says Utah should have demanded data on prescription refills before letting Doctronic launch.

“Mostly they're accepting the company's word on good faith that they're up to the task,” Bressman said.

Federal Regulators Take a Hands-Off Approach

The FDA has indicated it plans to take a hands-off approach under the current administration. An FDA spokesperson said the agency “is committed to encouraging medical innovation and helping bring promising new technologies to patients, while keeping safety at the center of every decision.”

Doctronic executives say their AI is part of the state-regulated practice of medicine. But the FDA is supposed to oversee AI that directly impacts medical care, a line some experts believe the company has crossed. Doctronic would not say whether it has sought FDA permission.

“Our goal here is really just to meet patients where they need healthcare,” said Dr. Adam Oskowitz, who co-founded the company. “We try not to get too deep into the weeds on the regulatory side.”

What This Means for Iowa Patients

For now, Doctronic and similar companies are likely to expand across states with different regulatory approaches. Daniel Aaron of the University of Utah's law school warns that rushing into AI prescribing could backfire.

“Companies may benefit in the short term by expanding their business models and kind of having the technology go beyond the evidence,” Aaron said. “But in the long-term, I think they risk compromising public trust and fueling backlash.”

Iowa patients and lawmakers will be watching closely as the debate over AI in healthcare continues to unfold.